Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Dose Range-Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults With Uncontrolled Asthma at Risk of Exacerbations (LEVANTE)

NCT06529419 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06529419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06529419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Dose Range-Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults With Uncontrolled Asthma at Risk of Exacerbations (LEVANTE)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
August 30, 2024
Completion date
February 4, 2026
Enrollment
537 (actual)
Sites
196

Conditions

As the registry lists them; a condition with its own page is linked.

asthma